Nuwiq (Vihuma) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of hemophilia a, limitations of plasma-derived therapies, expansion of recombinant protein technologies, improved patient survival rates, growth of specialized hemophilia treatment centers.

The growth in the forecast period can be attributed to increasing demand for personalized dosing regimens, rising adoption of long-term prophylaxis, expansion of recombinant therapy pipelines, growing investments in rare blood disorder research, increasing home infusion adoption. Major trends in the forecast period include increasing adoption of recombinant coagulation therapies, rising preference for human cell line-derived factor viii, growing focus on prophylactic hemophilia management, expansion of home-based treatment models, enhanced emphasis on treatment safety and purity.

The increasing prevalence of hemophilia A is anticipated to drive the growth of the Nuwiq (Vihuma) market in the future. Hemophilia A is a genetic bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII, which results in prolonged bleeding. The prevalence of hemophilia A is on the rise due to better diagnostic methods, greater awareness, and improved patient survival rates. Nuwiq (Vihuma) assists in managing hemophilia A by supplying a recombinant form of factor VIII, which replaces the missing or deficient clotting protein, enabling proper blood clotting and preventing or controlling bleeding episodes. For example, in November 2024, the National Institutes of Health (NIH), a leading medical research agency in the U.S., reported that in the UK, between April 2022 and March 2023, 6,662 males were diagnosed with hemophilia A. Thus, the growing global prevalence of hemophilia A is contributing to the expansion of the Nuwiq (Vihuma) market.

The growing healthcare spending is expected to drive the growth of the Nuwiq (Vihuma) market in the future. Healthcare expenditure refers to the overall spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. The rise in healthcare spending is fueled by factors such as an aging population, the increasing prevalence of chronic diseases, and a higher demand for healthcare services. This increase in healthcare spending benefits Nuwiq (Vihuma) by providing the necessary funding for the development, availability, and distribution of advanced hemophilia treatments, thereby enhancing patient access and supporting the inclusion of personalized therapies in treatment plans. For example, in May 2024, a report from the Office for National Statistics, a UK-based government agency, revealed that total healthcare expenditure grew by 5.6% in nominal terms between 2022 and 2023, compared to a 0.9% growth in 2022. As a result, the rise in healthcare spending is propelling the growth of the Nuwiq (Vihuma) market.

The growing emphasis on personalized medicine is expected to further fuel the growth of the Nuwiq (Vihuma) market. Personalized medicine refers to medical treatments tailored to an individual’s genetic, environmental, and lifestyle characteristics to enhance effectiveness and reduce side effects. The demand for personalized medicine is rising due to advancements in genetic research, heightened awareness of personalized healthcare, and the increasing recognition that tailored therapies provide better efficacy and fewer side effects compared to conventional treatments. Nuwiq (Vihuma) contributes to personalized medicine by offering a customized recombinant factor VIII therapy with individualized dosing and treatment plans, optimizing efficacy and minimizing risks for patients with hemophilia A. For instance, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, noted that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from the six approvals in 2022. As a result, the growing focus on personalized medicine is expected to drive the expansion of the Nuwiq (Vihuma) market.

Major companies operating in the nuwiq (vihuma) market are Octapharma AG.

North America was the largest region in the nuwiq (vihuma) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuwiq (vihuma) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuwiq (vihuma) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the nuwiq and vihuma market by increasing costs of imported bioreactor equipment, recombinant protein raw materials, purification systems, and cold-chain distribution services. Europe and North America are most affected due to reliance on cross-border biologics manufacturing, while Asia-Pacific faces higher costs in therapy importation and storage. These tariffs are contributing to increased treatment expenses and procurement challenges for healthcare providers. However, they are also supporting domestic biologics production, localized plasma-free manufacturing investments, and strengthened regional supply chains for rare disease therapies.

The nuwiq (vihuma) market research report is one of a series of new reports that provides nuwiq (vihuma) market statistics, including nuwiq (vihuma) industry global market size, regional shares, competitors with a nuwiq (vihuma) market share, detailed nuwiq (vihuma) market segments, market trends and opportunities, and any further data you may need to thrive in the nuwiq (vihuma) industry. This nuwiq (vihuma) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nuwiq (Vihuma) is a recombinant human coagulation factor VIII therapy developed for the treatment and prevention of bleeding episodes in patients with hemophilia A. It works by replacing the missing or deficient factor VIII, thereby supporting normal blood clotting.

The main indications for Nuwiq (Vihuma) include on-demand treatment, prophylaxis, and perioperative management. On-demand treatment involves administering the medication to control or stop bleeding episodes as they occur in patients with hemophilia. Nuwiq is distributed through direct sales, pharmacies, and online pharmacies, and is used in various settings such as hospitals, home care, and specialized clinics.

The nuwiq (vihuma) market consists of sales of hemophilia treatment kits, coagulation testing kits and prothrombin complex concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.